The Pentagon on Friday briefly added WuXi AppTec to a list of companies that aid the Chinese military before withdrawing the filing with no explanation. If the list is reposted as is, the designation would heighten scrutiny of the biotech supplier and make it a target of the recently passed Biosecure Act that restricts federal contracts with biopharma suppliers that are deemed foreign adversaries. Biosecure defers to the Pentagon’s 1260H list of Chinese military companies. The ultimate decision

SACRAMENTO, Calif., Feb. 13, 2026 /PRNewswire/ -- Lunai Bioworks (NASDAQ: LNAI), an AI-powered biotech and biodefense company, was featured on CNBC's Business Minute. Company CEO David Weinstein shared how the company is using its proprietary AI platform to scale therapeutic discovery and strengthen biodefense preparedness. "We are deploying AI to accelerate discovery in CNS disease and biodefense," said David Weinstein, Chief Executive Officer of Lunai Bioworks. "Our platform is built to scale

London, Mayfair based Norisia introduces a more intelligent and considered approach to daily wellness, uniting artificial intelligence with human bioscience. Artificial intelligence allows us to analyse biomedical research at scale while maintaining scientific discipline and structural integrity in every model we develop.” — Dr Obi Okeke, Biochemist LONDON, UNITED KINGDOM, MAYFAIR, UNITED KINGDOM, February 13, 2026 / EINPresswire.com / -- London, United Kingdom – Norisia, a Mayfair based healthc

Eli Lilly and Innovent's $8.8 billion new partnership, China's indictment of AstraZeneca and Madrigal Pharmaceuticals' latest metabolic dysfunction-associated steatohepatitis deal made our news this week. Eli Lilly and Innovent Biologics have deepened their ties with a new type of deal. China has indicted AstraZeneca and its former top exec in the country following investigations that emerged in 2024. Madrigal has signed a potential $4.4 billion siRNA deal with a Chinese biotech. And mo

Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides first fiscal quarter 2026 financial results CRANFORD, N.J., Feb. 13, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today reported financial results for the fiscal first quarter ended December 31, 2025, and provided a business update. "The first quarter of fiscal 2026 ma

GALWAY, Ireland, Feb. 13, 2026 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced U.S. Food and Drug Administration (FDA) clearance of the Stealth AXiS™ surgical system, a next-generation platform that brings planning, navigation, and robotics together into a single, intelligent system for spine surgery. Continue Reading Stealth AXiS™ surgical system The Stealth AXiS™ system is cleared for spine procedures in the United States, with an underlying arc

Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides first fiscal quarter 2026 financial results CRANFORD, N.J., Feb. 13, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal first quarter ended December 31, 2025, and provide

Peer-reviewed independent bench testing examines the TransForm™ mitral valve repair ring and highlights lifetime management considerations in cardiac surgery. Our findings demonstrate that the TransForm™ ring does indeed circularize and can anchor a balloon-expandable THV to facilitate TMViR.” — (Allen et. al, 2026) DENVER, CO, UNITED STATES, February 13, 2026 / EINPresswire.com / -- Genesee BioMedical, Inc. acknowledges the recent publication of a new peer-reviewed, open-access article in Struc

Eli Lilly is challenging a decision over how the FDA classified its experimental, next-gen obesity shot, in a case that could affect the ability of compounders to rival it. On Thursday, Lilly filed a notice to appeal a September district court decision that said the FDA didn’t violate the law when it decided to classify retatrutide as a drug instead of a biologic. Lilly is bringing the case to the US Court of Appeals for the Seventh Circuit. How a product is classified determines what marketing

Increased revenue by 105% year-over-year (YoY) to $2.2 million in fiscal Q3 Maintain fiscal year 2026 revenue guidance of $8-10 million $22.3 million pro forma cash, cash equivalents, restricted cash and marketable securities, including net proceeds from recent PIPE transaction, expected to provide runway into calendar 2027 Signed binding letter of intent for XTL Biopharmaceuticals to acquire 85% of Beyond Air's subsidiary NeuroNOS; Beyond Air to receive up to $32.5 million from the combina